Efficacy of rofecoxib for pain control after knee arthroscopy: a prospective, randomized, double-blinded clinical trial.
To determine if rofecoxib 50 mg administered 1 hour preoperatively to patients undergoing arthroscopic knee surgery reduces postoperative pain, provides a narcotic-sparing effect, and reduces time spent in recovery. Prospective, randomized, double-blinded clinical trial. Fifty patients (age range, 30 to 60 years) undergoing knee arthroscopy under spinal anesthesia were randomized to receive either 50 mg of rofecoxib or placebo 1 hour preoperatively. Postoperatively, pain was assessed in recovery, 8 hours postoperatively, and 24 hours postoperatively, using a 100-mm visual analog scale. Pain medication usage was monitored for 24 hours and time in recovery room was determined. Mann-Whitney tests determined significance between groups. Patients in the rofecoxib group showed significantly lower pain scores at 8 and 24 hours postoperatively. They also showed a significant reduction in postoperative narcotic consumption. Rofecoxib 50 mg as a single preoperative dose should be considered as part of a perioperative analgesic plan in arthroscopic knee surgery. Level I, Therapeutic Study (randomized controlled trial).